{"name":"Assembly Biosciences","slug":"assembly-bio","ticker":"ASMB","exchange":"NASDAQ","domain":"assemblybio.com","description":"Assembly Biosciences, Inc., a biotechnology company, develops therapeutic candidates for the treatment of viral diseases worldwide. Its pipeline includes long-acting helicase-primase inhibitors candidates, including ABI-5366 and ABI-1179, which are in Phase 1 clinical studies for recurrent genital herpes; and ABI-6250, an orally bioavailable hepatitis delta virus entry inhibitor that is in Phase 1a clinical study for the treatment of chronic hepatitis delta virus (HDV) infection. The company also develops ABI-4334, an orally bioavailable next generation capsid assembly modulator that is in Phase 1b study clinical trial for the treatment of chronic hepatitis B virus (HBV) infection; and ABI-7272, an oral broad-spectrum NNPI for the treatment of transplant-associated herpesviruses. It has an option, license, and collaboration agreement with Gilead Sciences, Inc. for the research and development of virology therapies. The company was formerly known as Ventrus Biosciences, Inc. and changed","hq":"San Diego, CA","founded":0,"employees":"73","ceo":"Jason A. Okazaki","sector":"Hepatitis B / Virology","stockPrice":30.81,"stockChange":-0.91,"stockChangePercent":-2.87,"marketCap":"$490M","metrics":{"revenue":72303000,"revenueGrowth":-12.8,"grossMargin":8.8,"rdSpend":64813000,"netIncome":-6122000,"cash":226600992,"dividendYield":0,"peRatio":385.1,"fiscalYear":"FY2025"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2033-06-01","label":"Vebicorvir patent cliff ($0.0B at risk)","drug":"Vebicorvir","type":"patent_expiry","sentiment":"negative"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"ABI-H3733 Solid Oral Dosage Form","genericName":"ABI-H3733 Solid Oral Dosage Form","slug":"abi-h3733-solid-oral-dosage-form","indication":"Other","status":"phase_1"}]}],"pipeline":[{"name":"ABI-H3733 Solid Oral Dosage Form","genericName":"ABI-H3733 Solid Oral Dosage Form","slug":"abi-h3733-solid-oral-dosage-form","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""}],"recentEvents":[{"date":"2024-02-27","type":"earnings","headline":"Assembly Biosciences Reports Fourth Quarter and Full Year 2023 Financial Results","summary":"Assembly Biosciences reported its fourth quarter and full year 2023 financial results, highlighting progress in its clinical pipeline and strong cash position.","drugName":"","sentiment":"neutral"},{"date":"2023-11-16","type":"deal","headline":"Assembly Biosciences Announces Collaboration with Gilead Sciences to Develop Novel Hepatitis B Therapies","summary":"Assembly Biosciences has entered into a collaboration with Gilead Sciences to develop novel hepatitis B therapies, expanding its pipeline and strengthening its position in the market.","drugName":"","sentiment":"positive"},{"date":"2023-08-14","type":"trial","headline":"Assembly Biosciences Announces Positive Topline Results from Phase 2a Trial of Vebicorvir in Chronic Hepatitis B","summary":"Assembly Biosciences has announced positive topline results from its Phase 2a trial of vebicorvir in chronic hepatitis B, demonstrating the potential of the therapy to treat the disease.","drugName":"","sentiment":"positive"}],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiugFBVV95cUxPZjN2bkY1TTc1UDlCaExOUkpzN19wU3ZkLXB0aFhfQ295NGZDRnJ3aUhqMEVaUEkwMTcwaVQ4RDNFQ3ZIOGNfYVhNZUhhUGZib1k5VTloa25tZUotMUc0eTBjSm1tdGVKZnlPV3M0SXN5TU51Ym9HZThjZnNLbVhNNy1wYWk2VklIMFlQZFdRU1NoNWJVLU00WEFsbWotR2xFd1pOWVVNRTUyRHd6MEVJM0RyaTA5a0hGa2c?oc=5","date":"2026-03-31","type":"pipeline","source":"Stock Titan","summary":"Assembly Biosciences (ASMB) CMO awarded 26,000 RSUs vesting through 2030 - Stock Titan","headline":"Assembly Biosciences (ASMB) CMO awarded 26,000 RSUs vesting through 2030","sentiment":"neutral"},{"date":"2026-03-30","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2026-03-20","type":"earnings","source":"simplywall.st","summary":"Assembly Biosciences (ASMB) Quarterly Profit Of US$22.1 Million Tests Bearish Narratives - simplywall.st","headline":"Assembly Biosciences (ASMB) Quarterly Profit Of US$22.1 Million Tests Bearish Narratives","sentiment":"neutral"},{"date":"2026-03-19","type":"earnings","source":"SEC EDGAR","summary":"10-K filed with SEC: 10-K","headline":"Annual Report (10-K) Filed","sentiment":"neutral"},{"date":"2026-03-19","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2026-01-22","type":"pipeline","source":"simplywall.st","summary":"Some Confidence Is Lacking In Assembly Biosciences, Inc. (NASDAQ:ASMB) As Shares Slide 27% - simplywall.st","headline":"Some Confidence Is Lacking In Assembly Biosciences, Inc. (NASDAQ:ASMB) As Shares Slide 27%","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiuwFBVV95cUxQQTJmdFI4Z0F0NDRyYnR6WE83aUJQR0dvdnEwM0dOUmZTOXA1TlM3ZTM3SnZSS2lGXzN4a0JwUlpsWGE0X2ZOaUU4b21HUkYxWUpuZldLeF9zeXFQWEEyRmd5Q3R5QVV6Q1pkZm40eXJZSnpKMmhFQkh0djJzNzdrbUwtQkdLN3VTY0NOMmdmejJtMkZZbjBJaTBSMzVMQmtTUU1GNUhZa01uMld6WmtTc0FSbTFXNXNrWU5F?oc=5","date":"2025-12-22","type":"pipeline","source":"Stock Titan","summary":"Drugmakers move closer to first new genital herpes treatment in 25 years - Stock Titan","headline":"Drugmakers move closer to first new genital herpes treatment in 25 years","sentiment":"neutral"},{"date":"2025-12-08","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi6gFBVV95cUxOZmhTemlRdko0YUY3T085WU1yVkxEVUllOTBvTmFuOWRLOGpDY0VSRUtydDdLTTdhQW03bXdlbVNEd2cxd2hBWEItMTNJWHhZblJrUjVPWDFRbnNxbzgzWG9Cbi1nZUp5NVV3TTg2LTFKdGRzRlpVRWRGd0RkTUNYS2dOenZtSHNXTElQaEg5ZDdZR0w0X3ZiSXBmdUk2QUlBSE51eXpyeW5Ga2xEX2NTd3U1VXJsMTV6eDRnWUVmNkxldXkxNmU2V3dkYjQ0dmY0WVVzMjJjRmhmQWw5MEVld2ZKTE03UzR6TkHSAe8BQVVfeXFMUEg3YUlRdUtlNXlBS0lVN0wyYkpkbTRVSnUzRGdsWjVsXzZKYWdaRUpxb2R5M3BuaFN3VmFFV0U4bzdRMkZHWFJDcGdRWEJGQUFoQ3h4Y1VHQVhZRjFVTjNuZ2FVTDU3RHh1RTJBVmxCQUwwUl9VVDZFQnVCcTB1TnZSUmxDNWJ3T1lPbnAtOExGUEJiYlloamIxenI2dnRIYUdIbHlRQm5XOFhZOHA3NWNYUnhqTXFxTW1melpwdVBnUk04bUxNQkZmS0pzRW9ONU1BNXRuQTRSOEJubC1xVkk1UzRld3FaT1NQWS1NM0U?oc=5","date":"2025-12-02","type":"pipeline","source":"simplywall.st","summary":"Companies Like Assembly Biosciences (NASDAQ:ASMB) Can Afford To Invest In Growth - simplywall.st","headline":"Companies Like Assembly Biosciences (NASDAQ:ASMB) Can Afford To Invest In Growth","sentiment":"neutral"},{"date":"2025-11-10","type":"earnings","source":"SEC EDGAR","summary":"10-Q filed with SEC: 10-Q","headline":"Quarterly Report (10-Q) Filed","sentiment":"neutral"},{"date":"2025-11-10","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2025-10-14","type":"pipeline","source":"simplywall.st","summary":"Assembly Biosciences Gains 13%, Insider Trades Reap Benefit - simplywall.st","headline":"Assembly Biosciences Gains 13%, Insider Trades Reap Benefit","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiuwFBVV95cUxQZnhWNHFndFJRSGRXcm44T0pOcENzbHB6Z3NIeWg2OU5xYjVaU2VTS3RfWkVPcnJDbU5FWXVvWnFwOVE2cnFQOGZJOHdta2JHTHlYMDZrVWpyX3dnVDVSbUs5aDlmaVV5eTN4MC1YbDFmbW9ybWVEWW1DT0NFa3R5eWZ4S01Jem1nVVBaanpNXzJYYnNQajY3N29zS1NsRV84UlN6TzFSVDhrU2xxWndPRGNMWGp4eEtFWVFV?oc=5","date":"2025-08-08","type":"trial","source":"Seeking Alpha","summary":"Assembly Biosciences: Positive Data Of ABI-5366 Brings 2 Fall Program Catalysts (ASMB) - Seeking Alpha","headline":"Assembly Biosciences: Positive Data Of ABI-5366 Brings 2 Fall Program Catalysts (ASMB)","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMiakFVX3lxTE9Bbko0ZmRDeWR6VFlFRHFFUWJ4QkFDWm5xOG9SczdlZmRWZGd6ZThlZWE5c092NGJfbWhjM1d3YnNXS1BXN2tXX1Y2QmhwNUJwLUVDYjIwcGM0elJKNXRCeFM3WVhWNENLd0E?oc=5","date":"2023-04-06","type":"pipeline","source":"GuruFocus","summary":"Richard D Dimarchi Net Worth (2026) - GuruFocus","headline":"Richard D Dimarchi Net Worth (2026)","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiaEFVX3lxTE5XSnB6UFVRamhoZ0I5WEJzM3daTkF4NDF4MGVNWjRRcTUwZjhQN1g0VDZkdkU4cXNybXd6WEgwZ21FQWhQeS0xUG9oSm9EclRwVFpkcDZnTlBBX3FiZVp0a28td3F1TXJJ?oc=5","date":"2022-09-13","type":"pipeline","source":"TradingView","summary":"ASMB Forecast — Price Target — Prediction for 2027 - TradingView","headline":"ASMB Forecast — Price Target — Prediction for 2027","sentiment":"neutral"}],"patents":[{"drugName":"Vebicorvir","drugSlug":"vebicorvir","patentNumber":"","type":"Patent Cliff","expiryDate":"2033-06-01","territory":"US","annualRevenue":0}],"drugCount":1,"phaseCounts":{"phase_1":1},"enrichmentLevel":3,"visitCount":1,"keyCompetitors":["Gilead Sciences","Merck & Co.","Bristol Myers Squibb"],"therapeuticFocus":["Hepatitis B","Virology"],"financials":{"source":"sec_edgar+yahoo","revenue":72303000,"revenuePeriod":"2025-12-31","revenueHistory":[{"value":72303000,"period":"2025-12-31"},{"value":28520000,"period":"2024-12-31"}],"grossProfit":null,"grossProfitHistory":[],"rdSpend":64813000,"rdSpendHistory":[{"period":"2025-12-31","value":64813000},{"period":"2024-12-31","value":55933000},{"period":"2023-12-31","value":48900000},{"period":"2022-12-31","value":69980000}],"sgaSpend":19608000,"operatingIncome":-12118000,"operatingIncomeHistory":[{"period":"2025-12-31","value":-12118000},{"period":"2024-12-31","value":-45420000},{"period":"2023-12-31","value":-64646000},{"period":"2022-12-31","value":-94114000}],"netIncome":-6122000,"netIncomeHistory":[{"period":"2025-12-31","value":-6122000},{"period":"2024-12-31","value":-40177000},{"period":"2023-12-31","value":-61228000},{"period":"2022-12-31","value":-93092000}],"eps":-0.55,"epsHistory":[{"period":"2025-12-31","value":-0.55},{"period":"2024-12-31","value":-6.69},{"period":"2023-12-31","value":-13.38},{"period":"2022-12-31","value":-23.04}],"cash":58450000,"cashHistory":[{"period":"2025-12-31","value":58450000},{"period":"2024-12-31","value":38344000},{"period":"2023-12-31","value":19841000},{"period":"2022-12-31","value":52418000}],"totalAssets":257590000,"totalLiabilities":50839000,"totalDebt":2628000,"equity":206751000,"operatingCashflow":-41093000,"operatingCashflowHistory":[{"period":"2025-12-31","value":-41093000},{"period":"2024-12-31","value":-51117000},{"period":"2023-12-31","value":22743000},{"period":"2022-12-31","value":-84463000}],"capex":-66000,"capexHistory":[{"period":"2025-12-31","value":-66000},{"period":"2024-12-31","value":-28000},{"period":"2023-12-31","value":-255000},{"period":"2022-12-31","value":-102000}],"freeCashflow":-41159000,"dividendsPaid":null,"buybacks":null,"employees":73,"segmentRevenue":[],"geographicRevenue":[],"quarterly":{"income":[{"sga":5420000,"ebit":19799000,"ebitda":19831000,"period":"2025-12-31","revenue":42469000,"epsBasic":null,"netIncome":22090000,"rdExpense":17250000,"epsDiluted":null,"grossProfit":null,"operatingIncome":19799000},{"sga":5085000,"ebit":-10883000,"ebitda":-10851000,"period":"2025-09-30","revenue":10789000,"epsBasic":-0.72,"netIncome":-9196000,"rdExpense":16587000,"epsDiluted":-0.72,"grossProfit":null,"operatingIncome":-10883000},{"sga":4594000,"ebit":-11093000,"ebitda":-11061000,"period":"2025-06-30","revenue":9626000,"epsBasic":-1.33,"netIncome":-10198000,"rdExpense":16125000,"epsDiluted":-1.33,"grossProfit":null,"operatingIncome":-11093000},{"sga":4509000,"ebit":-9941000,"ebitda":-9908000,"period":"2025-03-31","revenue":9419000,"epsBasic":-1.17,"netIncome":-8818000,"rdExpense":14851000,"epsDiluted":-1.17,"grossProfit":null,"operatingIncome":-9941000},{"sga":4609000,"ebit":-11532000,"ebitda":-11500000,"period":"2024-12-31","revenue":7357000,"epsBasic":null,"netIncome":-10335000,"rdExpense":14280000,"epsDiluted":null,"grossProfit":null,"operatingIncome":-11532000},{"sga":null,"ebit":null,"ebitda":null,"period":"2024-09-30","revenue":null,"epsBasic":-1.51,"netIncome":null,"rdExpense":null,"epsDiluted":-1.51,"grossProfit":null,"operatingIncome":null}]},"ciks":null,"lastFiledAt":null},"yahoo":{"currentPrice":30.81,"previousClose":31.72,"fiftyTwoWeekHigh":39.71,"fiftyTwoWeekLow":12.19,"fiftyTwoWeekRange":"12.19 - 39.71","fiftyDayAverage":28.7,"twoHundredDayAverage":28.6,"beta":0,"enterpriseValue":279995424,"forwardPE":-13.5,"priceToBook":2.47,"priceToSales":6.89,"enterpriseToRevenue":3.94,"enterpriseToEbitda":-20.87,"pegRatio":0,"ebitda":-13418750,"ebitdaMargin":-18.9,"freeCashflow":0,"operatingCashflow":0,"totalDebt":2491000,"debtToEquity":1.3,"currentRatio":6.65,"returnOnAssets":-5.1,"returnOnEquity":-5.7,"analystRating":"1.0 - Strong Buy","recommendationKey":"strong_buy","numberOfAnalysts":4,"targetMeanPrice":48.75,"targetHighPrice":62,"targetLowPrice":40,"dividendRate":0,"payoutRatio":0,"fiveYearAvgDividendYield":0,"exDividendDate":0,"insiderHeldPercent":32.4,"institutionHeldPercent":59.5,"sharesOutstanding":15892608,"floatShares":7520420,"sharesShort":1557158,"shortRatio":15.91,"shortPercentOfFloat":9.8,"epsTrailing":0.08,"epsForward":-2.28,"revenuePerShare":5.24,"bookValue":12.5,"officers":[{"age":49,"name":"Mr. Jason A. Okazaki J.D.","title":"CEO, President & Director"},{"age":53,"name":"Dr. William E. Delaney IV, Ph.D.","title":"Chief Scientific Officer"},{"age":47,"name":"Dr. Anuj  Gaggar M.D., Ph.D.","title":"Chief Medical Officer"},{"age":38,"name":"Ms. Jeanette M. Bjorkquist","title":"Principal Financial Officer, Executive Director of Accounting & Treasury"},{"age":null,"name":"Mr. Shannon  Ryan","title":"Senior Vice President of Investor Relations, Corporate Affairs & Alliance Management"},{"age":null,"name":"Ms. Jennifer A. Troia MHROD, SHRM-SCP, SPHR","title":"Chief Human Resources Officer"},{"age":45,"name":"Dr. Nicole S. White Ph.D.","title":"Chief Manufacturing Officer"},{"age":null,"name":"Ms. Katie  Kitrinos","title":"Senior VP of Preclinical Research & Development"}],"industry":"Biotechnology","irWebsite":"","website":"https://www.assemblybio.com","phone":"833 509 4583"}}